

Curriculum Vitae

Personal information Kira Blankenbach

Work experience

06/2021 to present

Clinical Assessor, Swissmedic Bern, Division
ATMP, Unit I - Switzerland -

- Evaluation of applications for clinical trials for ATMPs
- Evaluation of clinical trial reports for ATMPs
- Evaluation of adverse events during clinical trials for ATMPs
- Evaluation of applications for market authorisation of ATMPs
- RMP Assessments for ATMPs
- PSUR Assessments of ATMPs
- Pharmacovigilance Assessments for ATMPs
- Signal detection and assessment for ATMPs
- Risk communication for ATMPs
- Risk management and pharmacovigilance expert for GVP inspections at companies marketing ATMPs in Switzerland

10/2018 to 05/2021

Vigilance Assessor, Swissmedic Bern, Division
Pharmacovigilance, Unit Risk Management -
Switzerland -

- RMP Assessments
- PSUR Assessments

- Signal Assessment
- Risk communication
- Risk management expert for GVP inspections

01/2016 to 09/2018

Assessor, Paul-Ehrlich-Institut Langen, Unit Pharmacovigilance I - Germany -

- RMP Assessments for biologics
- PSUR Assessments for biologics
- Signal Assessment for biologics
- ICSR Assessment for biologics

01/2015 to 12/2015

Post-doc, Institute for general pharmacology and toxicology, Goethe- University Frankfurt am Main - Germany -

- Cell-based analyses of modulation of sphingosine kinases
- Modulation of sphingosine-1-phosphate receptors

Education and training

10/2011 to 12/2014

Doctoral fellowship Institute for general pharmacology and toxicology, MD, Goethe- University Frankfurt am Main - Germany -

10/2004 to 05/2011

Medical school, Goethe- University Frankfurt am Main - Germany -

Additional information

Publications

07/2020

“The WD40 repeat protein, WDR36, orchestrates sphingosine kinase-1 recruitment and phospholipase C- β activation by G_q-coupled receptors” (K. Blankenbach, G. Bruno, E. Wondra, A. Spohner, N. Aster, H. Vienken, S. Trautmann, N. Ferreirós, T. Wieland, P. Bruni, D. Meyer Zu Heringdorf), *Biochim Biophys Acta Mol Cell Biol Lipids*. (E-published

03/2020)

- 05/2019 “Natalizumab-associated progressive multifocal leukoencephalopathy in Germany” (K. Blankenbach, N. Schwab, B. Hofner, O. Adams, B. Keller-Stanislawski, C. Warnke), *Neurology*.
- 05/2018 “Bradykinin mediates myogenic differentiation in murine myoblasts through the involvement of SK1/Spns2/S1P₂ axis” (G. Bruno, F. Cencetti, C. Bernacchioni, C. Donati, K. Blankenbach, D. Thomas, D. Meyer zu Heringdorf, P. Bruni), *Cellular Signalling* (E-published 02/2018)
- 06/2016 “Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks” (K. Blankenbach, S. Schwalm, J. Pfeilschifter, D. Meyer zu Heringdorf), *Frontiers in Pharmacology*
- 07/2015 „Platelets from flowing blood attach to the inflammatory chemokine CXCL16 expressed in the endothelium of the human vessel wall“ (S. Meyer dos Santos, K. Blankenbach, K. Scholich, A. Dörr, N. Monsefi, M. Keese, B. Linke, H. Deckmyn, K. Nelson, S. Harder),

01/2015	“Upregulation of ABC transporters contributes to chemoresistance of sphingosine 1-phosphate lyase-deficient fibroblasts” (K. Ihlefeld, H. Vienken, R. F. Claas, K. Blankenbach, A. Rudowski, M. ter Braak, A. Koch, A. P. P. van Veldhoven, J. Pfeilschifter, D. Meyer zu Heringdorf), <i>The Journal of Lipid Research</i>
10/2014	“Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice” (F. Imeri, D. Fallegger, A. Zivkovic, S. Schwalm, G. Enzmann, K. Blankenbach, D. Meyer zu Heringdorf, T. Homann, B. Kleuser, J. Pfeilschifter, B. Engelhardt, H. Stark, A. Huwiler), <i>Neuropharmacology</i>
11/2013	“PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced $[Ca^{2+}]_i$ increases in renal mesangial cells (A. Koch, A. Völzke, B. Puff, K. Blankenbach, D. Meyer zu Heringdorf, A. Huwiler, J. Pfeilschifter), <i>Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids</i>
04/2013	“Transcatheter closure of multiple interatrial communications” (J. Masseli, S. Bertog, L. Stanczak, K. Blankenbach, N. Majunke, I. Reiffenstein, K. Renkhoff, K. Lehn, N. Wunderlich, H. Sievert), <i>Catheterization and Cardiovascular Interventions</i>
Projects Memberships	90. Kongress der deutschen Gesellschaft für Neurologie in Leipzig, Deutschland - Poster titled „Cases of progressive multifocal

leukoencephalopathy in Germany reported to the Federal Institute for Vaccines and Biomedicines from 2006 to 2017“ (K. Blankenbach, N. Schwab, C. Warnke, B. Keller-Stanislawski) -

- | | |
|---------|---|
| 11/2016 | Training <i>Spanish Agency of Medicines and Medical Devices</i> (AEMPS) in collaboration with <i>EU Network Training Centre</i> in Madrid, Spain
“Assessment of Drug-induced Liver Injury (DILI): Key Rules and Common Pitfalls” |
| 05/2015 | 11 th Spingolipid Club Meeting in Cesme, Turkey
- Poster and talk titled „Reverse modulation of G _q -coupled receptor-induced [Ca ²⁺] _i increases and sphingosine kinase-1 translocation by a WD repeat protein“ (K. Blankenbach, G. Bruno, H. Vienken, P. Bruni, D. Meyer zu Heringdorf) - |
| 06/2013 | 10 th Spingolipid Club Meeting in Santa Maria Degli Angeli, Assisi, Italien - Poster and talk titled „Modulation of S1P receptors by the fingolimod derivatives, ST968 and ST1071“ (K. Blankenbach, H. Stark, J. Pfeilschifter und D. Meyer zu Herigdorf) - |
| 05/2013 | Kurs „Experimentatorenfortbildung – Versuchstierkundlicher Kurs (entsprechend Kat. B der FELASA)“, CM Prognostik, Am Schloßpark 80, 65203 Wiesbaden |

Other Relevant Information